NCT01640288View on ClinicalTrials.gov

Imaging Regional Lung Defect Severity

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 10, 2018

Study Completion Date

August 10, 2018

Conditions
COPD
Interventions
DRUG

Perfluorinated Gas/Oxygen Mixture

19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour

OTHER

High Resolution CT of the Chest

High Resolution CT of the Chest, single visit

Trial Locations (1)

27705

Duke Image Analysis Laboratory, Durham

All Listed Sponsors
lead

Hal C Charles

OTHER

NCT01640288 - Imaging Regional Lung Defect Severity | Biotech Hunter | Biotech Hunter